Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
09 févr. 2023 07h30 HE
|
Kura Oncology, Inc.
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe...
Acute Myeloid Leukemia Diagnostics Market Set to Reach Valuation of USD 5,866.25 Million by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis
23 janv. 2023 07h50 HE
|
Data Bridge Market Research
NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research Published Latest Acute Myeloid Leukemia Diagnostics Market Study by in-depth analysis of the current scenario, the Market...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
10 déc. 2022 10h30 HE
|
Kura Oncology, Inc.
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated...
Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports
19 oct. 2022 06h13 HE
|
Growth Plus Reports
Pune, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute myeloid leukemia market is expected to clock US$ 4.31 billion by 2030 and to...
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape
06 sept. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis: 60+ Leading Companies are Working to Improve the Treatment Landscape DelveInsight’s...
Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting
04 avr. 2022 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
09 mars 2022 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia
06 janv. 2022 16h02 HE
|
Blue Note Therapeutics
SAN FRANCISCO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced...
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting
13 déc. 2021 08h00 HE
|
Aprea Therapeutics
60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Aprea...
AB Science reçoit l'approbation de la FDA pour initier une étude de phase I/II avec la molécule AB8939 dans le traitement de la leucémie myéloïde aiguë
22 nov. 2021 12h20 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE DE PHASE I/II AVEC LA MOLÉCULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE...